DNMT3A and postmenopausal osteoporosis: Furthermore, they investigated the possibility that targeted Dnmt3a inhibition may have a positive effect in preventing bone loss, by administration of the Dnmt3a inhibitor theaflavin-3,3′-digallate (TF-3) to ovariectomized female mice, as a model of postmenopausal osteoporosis.